{"analyses":[{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.70","groupDescription":"Week 1 Reduction \\>=30%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6658","paramType":"Odds Ratio (OR)","paramValue":"1.27","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.30","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"31.35","groupDescription":"Week 1 Reduction \\>=50%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3443","paramType":"Odds Ratio (OR)","paramValue":"3.07","statisticalMethod":"Regression, Logistic"},{"groupDescription":"Week 1 Reduction \\>=70%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9527","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.92","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.50","groupDescription":"Week 2 Reduction \\>=30%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0757","paramType":"Odds Ratio (OR)","paramValue":"2.25","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.91","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"22.42","groupDescription":"Week 2 Reduction \\>=50%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0659","paramType":"Odds Ratio (OR)","paramValue":"4.51","statisticalMethod":"Regression, Logistic"},{"groupDescription":"Week 2 Reduction \\>=70%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9380","statisticalMethod":"Regression, Logistic"},{"groupDescription":"Week 2 Reduction \\>=90%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9493","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.89","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.59","groupDescription":"Week 4 Reduction \\>=30%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0914","paramType":"Odds Ratio (OR)","paramValue":"2.02","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"1.08","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"9.61","groupDescription":"Week 4 Reduction \\>=50%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0359","paramType":"Odds Ratio (OR)","paramValue":"3.22","statisticalMethod":"Regression, Logistic"},{"groupDescription":"Week 4 Reduction \\>=70%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9538","statisticalMethod":"Regression, Logistic"},{"groupDescription":"Week 4 Reduction \\>=90%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9493","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"1.22","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.80","groupDescription":"Week 6 Reduction \\>=30%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0143","paramType":"Odds Ratio (OR)","paramValue":"2.66","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"1.28","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"13.74","groupDescription":"Week 6 Reduction \\>=50%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0176","paramType":"Odds Ratio (OR)","paramValue":"4.20","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"18.06","groupDescription":"Week 6 Reduction \\>=70%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1298","paramType":"Odds Ratio (OR)","paramValue":"3.53","statisticalMethod":"Regression, Logistic"},{"groupDescription":"Week 6 Reduction \\>=90%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9493","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.99","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.67","groupDescription":"Week 8 Reduction \\>=30%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0527","paramType":"Odds Ratio (OR)","paramValue":"2.15","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"1.02","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"7.12","groupDescription":"Week 8 Reduction \\>=50%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0457","paramType":"Odds Ratio (OR)","paramValue":"2.69","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.77","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"19.76","groupDescription":"Week 8 Reduction \\>=70%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0994","paramType":"Odds Ratio (OR)","paramValue":"3.91","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.07","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.86","groupDescription":"Week 8 Reduction \\>=90%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6977","paramType":"Odds Ratio (OR)","paramValue":"0.65","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.75","groupDescription":"Week 12 Reduction \\>=30%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1460","paramType":"Odds Ratio (OR)","paramValue":"1.76","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.92","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.01","groupDescription":"Week 12 Reduction \\>=50%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0742","paramType":"Odds Ratio (OR)","paramValue":"2.35","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.42","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.91","groupDescription":"Week 12 Reduction \\>=70%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5565","paramType":"Odds Ratio (OR)","paramValue":"1.44","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.28","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"10.35","groupDescription":"Week 12 Reduction \\>=90%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5623","paramType":"Odds Ratio (OR)","paramValue":"1.70","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"1.27","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.47","groupDescription":"Week 16 Reduction \\>=30%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0116","paramType":"Odds Ratio (OR)","paramValue":"2.86","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.96","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.70","groupDescription":"Week 16 Reduction \\>=50%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0615","paramType":"Odds Ratio (OR)","paramValue":"2.34","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.59","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.80","groupDescription":"Week 16 Reduction \\>=70%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3316","paramType":"Odds Ratio (OR)","paramValue":"1.68","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.19","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.33","groupDescription":"Week 16 Reduction \\>=90%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9946","paramType":"Odds Ratio (OR)","paramValue":"1.01","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"1.33","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.76","groupDescription":"Week 24 Reduction \\>=30%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0083","paramType":"Odds Ratio (OR)","paramValue":"2.99","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"1.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.88","groupDescription":"Week 24 Reduction \\>=50%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0513","paramType":"Odds Ratio (OR)","paramValue":"2.42","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"8.58","groupDescription":"Week 24 Reduction \\>=70%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1528","paramType":"Odds Ratio (OR)","paramValue":"2.48","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"0.21","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"9.65","groupDescription":"Week 24 Reduction \\>=90%: Logistic regression model included baseline average pain intensity at the index bone metastasis cancer pain site, baseline worst pain intensity at the index bone metastasis cancer pain site, treatment, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness).","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7251","paramType":"Odds Ratio (OR)","paramValue":"1.41","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 1: Reduction of >=30%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 1: Reduction of >=50%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 1: Reduction of >=70%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 1: Reduction of >=90%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 2: Reduction of >=30%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 2: Reduction of >=50%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 2: Reduction of >=70%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 2: Reduction of >=90%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 4: Reduction of >=30%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 4: Reduction of >=50%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 4: Reduction of >=70%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 4: Reduction of >=90%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 6: Reduction of >=30%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 6: Reduction of >=50%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 6: Reduction of >=70%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 6: Reduction of >=90%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 8: Reduction of >=30%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 8: Reduction of >=50%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 8: Reduction of >=70%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 8: Reduction of >=90%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 12: Reduction of >=30%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 12: Reduction of >=50%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 12: Reduction of >=70%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 12: Reduction of >=90%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"2"},{"groupId":"OG003","value":"24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 16: Reduction of >=30%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"},{"groupId":"OG003","value":"18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 16: Reduction of >=50%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"0"},{"groupId":"OG003","value":"11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 16: Reduction of >=70%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG003","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 16: Reduction of >=90%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"},{"groupId":"OG003","value":"25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 24: Reduction of >=30%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"},{"groupId":"OG003","value":"18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 24: Reduction of >=50%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG003","value":"9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 24: Reduction of >=70%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG003","value":"3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"title":"Week 24: Reduction of >=90%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"71"}],"units":"Participants"}],"description":"Daily worst pain intensity in the index bone metastasis cancer pain site was assessed by participants on an 11 point pain intensity NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores = more severity of pain. The participants recorded their daily worst pain at the painful site during the past 24 hours by choosing the appropriate number from 0 to 10 on IRT diaries. The Weeks 1, 2, 4, 6, 8, 12, 16 and 24 pain intensity value = mean of the daily worst pain intensity NRS scores for the 7 days prior to the each week. Number of participants with cumulative reduction of \\>= 30, 50, 70, and 90 % in daily worst pain intensity NRS score in the index bone metastasis cancer pain site from Baseline to Weeks 1, 2, 4, 6, 8, 12, 16 and 24 were reported. Participants might be reported more than once in the specified rows for a time point. Rows with only non-zero data for cumulative reduction at specified time points, for at least 1 reporting arm, are reported below.","groups":[{"description":"Participants received placebo matched to tanezumab SC once every 8 weeks for 24 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants in this discontinued treatment arm, received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and completed their treatment before the amendment.","id":"OG001","title":"Tanezumab 10 mg"},{"description":"Participants in this treatment group had received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and after the amendment they continued remaining treatment with tanezumab 20 mg SC once every 8 weeks.","id":"OG002","title":"Tanezumab 10/20 mg"},{"description":"Participants received tanezumab 20 mg SC once every 8 weeks for 24 weeks.","id":"OG003","title":"Tanezumab 20 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The mITT analysis set was analyzed. Multiple imputation method was applied. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure and ''number analyzed'' signifies participants evaluable at specified time points.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 1, 2, 4, 6, 8, 12, 16 and 24","title":"Number of Participants With Reduction of >=30, 50, 70 and 90% From Baseline in Daily Worst Pain Intensity NRS Score in the Index Bone Metastasis Cancer Pain Site at Weeks 1, 2, 4, 6, 8, 12, 16 and 24","type":"SECONDARY","unitOfMeasure":"Participants"}